Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOI, etc.
To investigate treatment strategies and prognostic factors in children with relapsed acute lymphoblastic leukemia (ALL).
A retrospective cohort study enrolled 86 children diagnosed with and relapsed from ALL between 2015 and 2019. Kaplan-Meier method and Cox regression model were applied for analysis.
The median follow-up after relapse was 36 months. The 4-year overall survival (OS) rate was 59%. Multivariate analysis (based on the subgroup receiving induction chemotherapy) identified high-risk relapse and minimal residual disease (MRD) ≥0.01% after induction therapy as independent risk factors for 4-year OS (P<0.05). The introduction of chimeric antigen receptor T-cell (CAR-T) therapy in 2017 significantly improved the 4-year OS rate in children with relapsed ALL (61% vs 26%, P=0.030). According to relapse risk stratification, all low-risk patients survived whether receiving chemotherapy alone or CAR-T therapy. Among intermediate-risk patients, those achieving MRD negativity after re-induction had a high survival rate with chemotherapy (12/13), whereas MRD-positive patients had a high survival rate with CAR-T combined with transplantation (7/8). In high-risk patients, the survival rate for those receiving transplantation (after chemotherapy or CAR-T) was 60% to 62.5%, significantly higher than that of the chemotherapy-alone group (0% survival). The 4-year OS rate for the CAR-T followed by hematopoietic stem cell transplantation group was higher than that of the CAR-T alone group (75% vs 24%, P=0.067).
An individualized treatment strategy based on risk stratification combined with MRD status is recommended for children with relapsed ALL.
OA under CC BY-NC-ND 4.0 license
Comments on this article